JAMA (Journal of the American Medical Association)
Відкрити в Telegram
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
Показати більше📈 Аналітичний огляд Telegram-каналу JAMA (Journal of the American Medical Association)
Канал JAMA (Journal of the American Medical Association) (@jamaupdates) у мовному сегменті Англійська є активним учасником. На даний момент спільнота об'єднує 16 793 підписників, посідаючи 1 488 місце в категорії Медицина та 2 227 місце у регіоні США.
📊 Показники аудиторії та динаміка
З моменту свого створення невідомо, проект продемонстрував стрімке зростання, зібравши аудиторію у 16 793 підписників.
За останніми даними від 31 жовтня, 2026, канал демонструє стабільну активність. Хоча за останні 30 днів спостерігається зміна кількості учасників на 278, а за останні 24 години на 4, загальне охоплення залишається високим.
- Статус верифікації: Не верифікований
- Рівень залученості (ER): Середній показник залученості аудиторії становить 4.14%. Протягом перших 24 годин після публікації контент зазвичай збирає 1.91% реакцій від загальної кількості підписників.
- Охоплення публікацій: В середньому кожен допис отримує 695 переглядів. Протягом першої доби публікація в середньому набирає 320 переглядів.
- Реакції та взаємодія: Аудиторія активно підтримує контент: середня кількість реакцій на один пост – 1.
- Тематичні інтереси: Контент зосереджений навколо ключових тем, таких як patient, disease, treatment, drug, guideline.
📝 Опис та контентна політика
Автор описує ресурс як майданчик для висловлення суб'єктивної думки:
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
Завдяки високій частоті оновлень (останні дані отримано 01 листопада, 2026), канал підтримує актуальність та високий рівень охоплення публікацій. Аналітика показує, що аудиторія активно взаємодіє з контентом, що робить його важливою точкою впливу в категорії Медицина.
16 793
Підписники
+424 години
+377 днів
+27830 днів
Завантажуємо дані
Схожі канали
Хмара тегів
Вхідні та вихідні згадування
---
---
---
---
---
---
Залучення підписників
листопад '26лист '26
листопад '26
+8
в 0 каналах
жовтень '26
+291
в 0 каналах
Get PRO
вересень '26
+301
в 0 каналах
Get PRO
серпень '26
+361
в 0 каналах
Get PRO
липень '26
+440
в 0 каналах
Get PRO
червень '26
+422
в 1 каналах
Get PRO
травень '26
+584
в 0 каналах
Get PRO
квітень '26
+437
в 0 каналах
Get PRO
березень '26
+217
в 0 каналах
Get PRO
лютий '26
+247
в 0 каналах
Get PRO
січень '26
+321
в 0 каналах
Get PRO
грудень '25
+277
в 0 каналах
Get PRO
листопад '25
+366
в 2 каналах
Get PRO
жовтень '25
+164
в 0 каналах
Get PRO
вересень '25
+12
в 0 каналах
Get PRO
серпень '25
+29
в 0 каналах
Get PRO
липень '25
+30
в 0 каналах
Get PRO
червень '25
+17
в 0 каналах
Get PRO
травень '25
+9
в 0 каналах
Get PRO
квітень '25
+5
в 0 каналах
Get PRO
березень '25
+17
в 0 каналах
Get PRO
лютий '25
+12
в 0 каналах
Get PRO
січень '25
+18
в 1 каналах
Get PRO
грудень '24
+237
в 0 каналах
Get PRO
листопад '24
+1 122
в 0 каналах
Get PRO
жовтень '24
+1 120
в 0 каналах
Get PRO
вересень '24
+1 527
в 1 каналах
Get PRO
серпень '24
+1 128
в 1 каналах
Get PRO
липень '24
+1 216
в 0 каналах
Get PRO
червень '24
+781
в 1 каналах
Get PRO
травень '24
+797
в 1 каналах
Get PRO
квітень '24
+808
в 1 каналах
Get PRO
березень '24
+821
в 2 каналах
Get PRO
лютий '24
+753
в 1 каналах
Get PRO
січень '24
+768
в 0 каналах
Get PRO
грудень '23
+716
в 1 каналах
Get PRO
листопад '23
+96
в 1 каналах
Get PRO
жовтень '23
+86
в 0 каналах
Get PRO
вересень '23
+73
в 0 каналах
Get PRO
серпень '23
+90
в 0 каналах
Get PRO
липень '23
+107
в 0 каналах
Get PRO
червень '23
+105
в 0 каналах
Get PRO
травень '23
+169
в 0 каналах
Get PRO
квітень '23
+128
в 0 каналах
Get PRO
березень '23
+84
в 0 каналах
Get PRO
лютий '23
+75
в 0 каналах
Get PRO
січень '23
+71
в 0 каналах
Get PRO
грудень '22
+74
в 0 каналах
Get PRO
листопад '22
+149
в 0 каналах
Get PRO
жовтень '22
+90
в 0 каналах
Get PRO
вересень '22
+138
в 0 каналах
Get PRO
серпень '22
+77
в 0 каналах
Get PRO
липень '22
+50
в 0 каналах
Get PRO
червень '22
+96
в 0 каналах
Get PRO
травень '22
+75
в 0 каналах
Get PRO
квітень '22
+80
в 0 каналах
Get PRO
березень '22
+65
в 0 каналах
Get PRO
лютий '22
+26
в 0 каналах
Get PRO
січень '22
+56
в 0 каналах
Get PRO
грудень '21
+44
в 0 каналах
Get PRO
листопад '21
+39
в 0 каналах
Get PRO
жовтень '21
+61
в 0 каналах
Get PRO
вересень '21
+66
в 0 каналах
Get PRO
серпень '21
+65
в 0 каналах
Get PRO
липень '21
+96
в 0 каналах
Get PRO
червень '21
+120
в 0 каналах
Get PRO
травень '21
+130
в 0 каналах
Get PRO
квітень '21
+812
в 0 каналах
| Дата | Залучення підписників | Згадування | Канали | |
| 01 листопада | +8 |
Дописи каналу
Are GLP-1 Drugs Safe in Frailty?
https://jamanetwork.com/journals/jama/fullarticle/2856274
This Medical News article discusses an analysis of cardiovascular benefits and safety of semaglutide use in trial participants with frailty, defined by accumulated age-related health deficits.
| 2 | Pennsylvania Tops 1000 Measles Cases
https://jamanetwork.com/journals/jama/fullarticle/2856273
This Medical News article discusses ongoing measles outbreaks in Pennsylvania and other US states amid declining vaccine coverage. | 453 |
| 3 | JAMA Editors' Summary Podcast October 30, 2026
https://jamanetwork.com/journals/jama/fullarticle/2856302
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA. | 448 |
| 4 | FDA Approves New Drug to Treat Herpes Simplex Virus Lesions
https://jamanetwork.com/journals/jama/fullarticle/2856280
The US Food and Drug Administration (FDA) approved a new treatment for adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus (HSV). | 444 |
| 5 | RNAi Targeting Hepatic AGT to Block RAAS Pathway in Hypertension
https://jamanetwork.com/journals/jamacardiology/fullarticle/2856139
Hypertension is the most important modifiable risk factor for cardiovascular diseases, which are the leading causes of morbidity and mortality. It remains a global health concern as diagnosis, treatment, and control rates remain poor, with less than 25% of patients achieving the guideline-recommended systolic blood pressure (BP) target of less than 130 mm Hg. Cardiovascular outcome studies, such as the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and the Systolic Blood Pressure Intervention Trial (SPRINT), have demonstrated the cardiovascular outcome benefits of intensive BP control and have influenced hypertension guidelines globally. Most guidelines recommend a BP target of less than 130 mm Hg, which has also contributed to accentuating poor control rates. | 461 |
| 6 | A Review of Low Back Pain
https://jamanetwork.com/journals/jama/fullarticle/2855996
To the Editor I read with great interest the comprehensive narrative Review on low back pain, which provided an excellent overview of the epidemiology, diagnosis, and management of this prevalent condition. However, I believe the evidence for skeletal muscle relaxants in acute nonspecific low back pain was presented in a manner that overstated their clinical value. | 545 |
| 7 | A Review of Low Back Pain
https://jamanetwork.com/journals/jama/fullarticle/2855997
To the Editor A recent review synthesized articles on nonspecific low back pain from 2005 to 2026. After reading this article, we believe that the recommendation against routine spinal imaging in patients without alarm symptoms or obvious clinical history warrants additional, more nuanced discussion. The designation of low back pain as “nonspecific” is contingent upon excluding identifiable structural pathology. However, several clinically meaningful diagnoses are not identifiable by history or physical examination and require imaging for accurate characterization and management. | 502 |
| 8 | Massachusetts Marketplace Disenrollment Following Enhanced Subsidy Expiration
https://jamanetwork.com/journals/jama/fullarticle/2855998
This study uses administrative enrollment data from the Massachusetts Health Marketplace to analyze patterns of Marketplace disenrollment when enhanced subsidies expired vs end-of-year disenrollment in prior years. | 456 |
| 9 | Wagering on Unfinished Experiments—Prediction Markets and Clinical Trial Integrity
https://jamanetwork.com/journals/jama/fullarticle/2855990
This Viewpoint discusses the potential impact on recruitment, retention, measurement, or evidence generation after a prediction market platform announced it would host betting on the outcomes of clinical trials and US Food and Drug Administration regulatory reviews, noting that policy action is needed to ensure that prediction markets do not undermine the public interest. | 428 |
| 10 | Editorials
https://jamanetwork.com/journals/jama/fullarticle/2855999 | 396 |
| 11 | The Future of Coronary Interventions
https://jamanetwork.com/journals/jamacardiology/fullarticle/2855708
This Viewpoint provides a brief glance at the future state of coronary intervention in the years ahead. | 510 |
| 12 | Parental Diabetes and Risk of Cardiovascular Disease in Offspring
https://jamanetwork.com/journals/jamacardiology/fullarticle/2855710
To the Editor First, the study by Mo et al classified maternal diabetes into gestational and pregestational diabetes but did not account for pregnancy glycemic control. Poorly controlled vs well-controlled diabetes may lead to substantially different offspring risks, and this distinction is critical for clinical counseling and intervention. In Sweden, prenatal diabetes care is universally accessible and high quality. In regions with limited screening or glycemic management, observed risk ratios could be significantly higher. We suggest replication in diverse global cohorts with varying levels of diabetes management. | 521 |
| 13 | Parental Diabetes and Risk of Cardiovascular Disease in Offspring—Reply
https://jamanetwork.com/journals/jamacardiology/fullarticle/2855709
In Reply We thank He and colleagues for their thoughtful comments regarding our study on maternal diabetes and offspring cardiovascular disease (CVD) risk. We appreciate their interest in our work and their valuable perspectives on potential mechanisms and future research directions. | 446 |
| 14 | Massive Aortic Root Air Lock During LVAD Implantation
https://jamanetwork.com/journals/jamacardiology/fullarticle/2855711
This case report discusses a massive air lock within the aortic root discovered during separation from cardiopulmonary bypass in a man in his 60s who underwent durable left ventricular assist device implantation. | 402 |
| 15 | Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer—Reply
https://jamanetwork.com/journals/jama/fullarticle/2855976
In Reply Dr Freund and colleagues raise 2 interesting points regarding the interpretation of the Hydra study findings. First, they argue that not all VTE events during follow-up can be attributed to missed PE at baseline and, as such, should not be labeled as diagnostic failures. | 440 |
| 16 | Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer
https://jamanetwork.com/journals/jama/fullarticle/2855977
To the Editor Dr Akerboom and colleagues reported that, among patients with active cancer and suspected pulmonary embolism (PE), the YEARS algorithm was noninferior to computed tomographic pulmonary angiography (CTPA) alone, with a 3-month diagnostic failure rate of 1.8% vs 5.5%. Although we welcome any strategy that limits CTPA in this population, the interpretation of this comparison, in particular of its control group, deserves scrutiny. | 486 |
| 17 | Diagnosis and Management of Acute Rhinosinusitis in Adults
https://jamanetwork.com/journals/jama/fullarticle/2855978
This JAMA Clinical Guidelines Synopsis summarizes the 2025 update of the American Academy of Otolaryngology–Head and Neck Surgery Foundation guideline on diagnosis and management of acute rhinosinusitis in adults. | 469 |
| 18 | Toward Coordinated Systems of Care for TIA—The Role and Scope of EDs
https://jamanetwork.com/journals/jamaneurology/fullarticle/2855738
In this issue of JAMA Neurology, Mamer and colleagues present national trends in the emergency department (ED)–based care of transient ischemic attack (TIA) from 2013 to 2021. The authors demonstrate remarkable increases in the rate of advanced imaging in the ED and decreases in the hospitalizations of this population. The marked increase in use of vascular imaging is reassuring to see, as the timely identification of significant atherosclerotic disease—especially carotid stenosis requiring revascularization—is a key step in lowering the risk of early recurrent stroke. | 705 |
| 19 | Error in Byline
https://jamanetwork.com/journals/jamaneurology/fullarticle/2855739
The Original Investigation titled “Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial,” published online July 27, 2026, and in the September issue, was corrected to add the study group to the byline and a supplement listing the nonauthor collaborators. This article was corrected online. | 593 |
| 20 | Errors in Text, Table 1, Figures 1 to 3, and Supplements
https://jamanetwork.com/journals/jamaneurology/fullarticle/2855740
In the Original Investigation titled “Effect of Electroacupuncture on Postherpetic Neuralgia: A Randomized Clinical Trial,” published online first on May 26, 2026, and in the July 2026 issue, there were errors in the article text, Table 1, Figures 1 and 3, and the caption of Figure 2; the protocol in Supplement 1; and eTables 2, 4, 7, 12, and 14, footnote d of eTable 5, and the captions for eFigures 1 and 2 in the original Supplement 2 (now Supplement 3). The author has provided a letter of explanation. This article was corrected online. | 528 |
